207_Combined course Presentations

Dutch Phase II trial “RADITUX”: Concurrent CT/RT using a hypofractionated scheme

To investigate 60-month OS in LA-NSCLC patients treated in Raditux trial: concurrent chemoradiotherapy +/- cetuximab, using a hypofractionation scheme of 24 x 2.75 Gy

 RT schedule: 24 x 2.75 Gy

 CT schedule: daily low dose cisplatin (6 mg/m 2 ) +/- weekly cetuximab